XHS

The Week

Hinge Health (HNGE) gained 2.2% this week to close at $97.67, beating the S&P 500 by roughly 2.47 percentage points, as the benchmark slipped 0.27%. The stock opened the week at $93.98, dipped to $91.52 on Monday and Tuesday, then climbed for three straight sessions. It hit an intraday high of $99.73 on Friday before easing back to close at $97.67, leaving the weekly range at 8.74%.

Key Events

News around Hinge Health this week was mostly about sector momentum and sell-side attention. On Monday it was named among 3 healthcare stocks showing why the sector still has momentum. On Tuesday, analysts at Bank of America picked up coverage of Hinge Health (NYSE:HNGE). By Thursday the stock appeared in a list of biotech names touching 52-week highs, alongside PGEN, EXEL, TWST and PBYI. There were no material company filings during the week, so the narrative was driven by analyst coverage and broader healthcare sentiment.

Analyst Ratings

Among 17 institutions covering Hinge Health, 9 rate it buy, 7 rate it overweight, 1 rates it hold, and none rate it underweight or sell. The consensus rating is buy, with a consensus target of $109.3125, about 11.92% above the current price of $97.67. Target prices range from $90 to $140, reflecting meaningful dispersion. Within the healthcare services industry, Hinge Health ranks 6th out of 53 names by analyst rating, with 17 institutions covering it versus an industry median of 7.

The Week Ahead

Macro data dominates the early part of next week. On Monday, the US S&P Global services PMI final and ISM non-manufacturing PMI are due, followed by international trade balance and goods trade balance on Tuesday, and weekly EIA crude and Cushing inventories on Wednesday. These releases may shape risk appetite and the relative strength of healthcare stocks, offering a backdrop for how high-valuation digital-health names like Hinge Health trade.

In Short

Hinge Health rose this week and outperformed the broader market, finishing just below its 52-week high of $99.73. Analyst ratings are heavily skewed towards buy or overweight, and the consensus target sits about 11.92% above the current price, pointing to a favourable external view. At the same time, the stock trades at around 73.46x P/E and 22.89x P/B, with target prices spread widely from $90 to $140, and the latest session showed small-lot flows leading while large-lot buying was limited. The tension between supportive ratings and rich valuation will likely be tested by next week’s services PMI data and broader risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.